Significant associations were observed between the visfatin -1535C>T polymorphism and HBV-HCC risk in the co-dominant model (TT versus CC: OR = 0.493, 95% CI = 0.313-0.778, P = 0.002), the recessive model (TT versus CT + CC: OR = 0.535, 95% CI = 0.362-0.791, P = 0.002), and the allelic model (allele T versus allele C: OR = 0.734, 95% CI = 0.58-0.950, P = 0.018). The gene discussed is NAMPT; the disease is hepatocellular carcinoma.